Peripheral Neuropathy Trial, Recruiting NCT06236750 Sponsor: MiMedx Group, Inc. Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06236750
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a diabetic foot ulcer or a venous leg ulcer that has not reduced in size by at least 50% after 4 weeks of standard treatments, such as wound cleaning, removal of dead tissue, infection control, blood sugar management (for diabetic foot ulcers), compression therapy (for venous leg ulcers), or moist wound dressings.

Who may not be able to join:

  • People who have an active or hidden infection in the affected area.
  • People who have health conditions that would make the risk of complications after a procedure too high.
  • People whose ulcer cannot be adequately cleaned of dead or damaged tissue (a process called debridement).
  • People whose ulcer, after cleaning, shows signs of continued tissue death early on due to poor blood flow to the wound area.
  • People whose wound involves multiple ulcer areas with exposed bone and no blood flow in the wound bed.
  • People who have had an allergic reaction to a type of antibiotic called aminoglycosides (such as gentamicin or streptomycin), as these are used during the manufacturing process of the treatment being studied.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Mason, MD, MiMedx Group, Inc.

Phone: 770-651-9100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
MiMedx Group, Inc.
Registry
ClinicalTrials.gov
Start date
4 August 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Efficacy Endpoint: Healing of Ulcers at 4 Weeks, 8 Weeks, and 12 Weeks; Safety Endpoint: Incidence of Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov